Alzheimer’s Early Detection: New Blood Tests for Adults Over 50
A blood test can now identify biological signatures of Alzheimer’s disease in adults as young as 53, often years before memory loss begins. The FDA has recently authorized the Lumipulse G pTau217/β-amyloid 1-42 Plasma test for use in hospital settings for patients already experiencing cognitive decline, potentially making early diagnosis more accessible for Americans.
How early can blood tests detect Alzheimer’s?
Researchers from the University of California, San Francisco, analyzed 1,350 adults aged 53 to 69 who showed no apparent dementia as part of the CARDIA study. They looked for two specific proteins: tau and beta-amyloid.
About 6% of these participants had high levels of both biomarkers. While these individuals showed no clear differences in language or global memory, they performed worse in executive functions and information processing speed.
The implications for the future were significant. Over a five-year period, those with these biomarkers faced a risk of rapid verbal memory decline that was 2.5 to 4 times higher, and a risk of mental slowing that was 3 to 4 times higher.
Why is early biological detection significant?
Early detection allows patients to address modifiable risk factors before severe symptoms emerge. Kristine Yaffe of the University of California explained that the pathology of Alzheimer’s starts years before symptoms appear, and early detection means patients can target these risks or seek other care.
Intervening early could potentially delay the onset of the disease. According to the research, up to 40% of dementia cases could be delayed by managing factors such as hypertension, cardiovascular diseases, depression, smoking, sleep disorders, social isolation, and physical activity.
What is the new FDA-authorized diagnostic tool?
The FDA has authorized the Lumipulse G pTau217/β-amyloid 1-42 Plasma test, developed by Fujirebio Diagnostics. This test measures the ratio between tau and beta-amyloid proteins in the plasma, which correlates to the presence of plaques in the brain.
FDA Commissioner Martin A. Makary noted that 10% of people aged 65 and older currently live with Alzheimer’s, a figure expected to double by 2050. Michelle Tarver stated that this authorization is an important step in making diagnosis easier and more accessible for patients at an earlier stage.
However, the FDA specifies that this tool is not for general screening. It is reserved for hospital environments and patients already showing cognitive decline, and the results must be interpreted alongside other clinical data.
What happens next for screening?
While the Lumipulse test improves the ability to spot the disease in symptomatic patients, systematic screening for healthy adults over 50 is not yet a reality. This remains a horizon for future research.
Future developments may focus on expanding these tests beyond hospital settings. If research continues to validate the link between biomarkers and long-term decline, clinicians could potentially use these tools to identify at-risk individuals much earlier in their adult lives.
Frequently Asked Questions
Who is the FDA-approved Lumipulse test intended for?
The test is reserved for use in hospital settings for patients who are already experiencing cognitive decline.
Which proteins are used to identify Alzheimer’s in these blood tests?
The tests look for beta-amyloid and tau proteins.
Can Alzheimer’s be delayed through lifestyle changes?
Yes, according to the source, up to 40% of dementia cases could be delayed by addressing factors like physical activity, smoking, hypertension, and social isolation.
Would you consider taking a blood test to identify your risk for Alzheimer’s years before symptoms appear?